This Week in Lancet Oncology

Premium

In Lancet Oncology this week, researchers in China report on the efficacy of gefitinib as a maintenance treatment for patients with locally advanced or metastatic non-small-cell lung cancer. The team randomly assigned 296 patients to receive either gefitinib or placebo within three to six week of chemotherapy, and found that progression-free survival was significantly longer with gefitinib compared to placebo.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The popular astrophysicist warned that apathy and even contempt for science in politics could lead to the end of informed democracy. 

In PLOS this week: Uncovering variants associated with diabetes-related kidney disease, a sequencing study of hepatitis E viruses circulating in Cambodia, and more.

Among Sacks' books was "Awakenings," which was later made into an Academy Award-winning film.

The popularity of the #sciencemoviequote Twitter trend showcases scientists' eclectic movie tastes and knack for puns.